Skip to main content
. 2012 Aug 24;7(8):e43882. doi: 10.1371/journal.pone.0043882

Figure 4. Low-level viremia by TaqMan v1 does not predict short-term virological failure.

Figure 4

A subset of patients (N = 279) with low-level viremia (40–250 copies/mL) by TaqMan v1 were followed longitudinally for a median of 3.2 months (IQR: 2.0–4.2 months). Patients initiated HAART at least 6 months prior, and treatment regimens remained unchanged over the course of follow-up. Samples from patients' latest follow-up visit were re-tested with the TaqMan v1 and Amplicor v1.5 assays. Overall 17% of patients had a detectable viral load by Amplicor v1.5 at their latest follow-up visit, while 38% were detectable by TaqMan v1. When patients were grouped according to their baseline TaqMan v1 pVL into 50 copies/mL strata we observed a stepwise increase in the proportion of patients with detectable pVL at their latest follow-up visit by both Amplicor v1.5 (red bars) and TaqMan v1 (blue bars). Consistent with previous results, more patients had detectable pVL by TaqMan v1 than by Amplicor v1.5 at follow-up in all strata.